Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024 April 24, 2024 12:45 Regulatory Read more
BioArctic and Eisai sign research evaluation agreement regarding BAN2802 April 20, 2024 09:40 Regulatory Read more
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed April 1, 2024 01:40 Regulatory Read more
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons March 22, 2024 12:30 Regulatory Read more
BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference March 7, 2024 06:30 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of February 29, 2024 February 29, 2024 18:30 Regulatory Read more
Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023 February 6, 2024 04:36 Regulatory Read more
The European Medicines Agency’s Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab January 11, 2024 07:00 Regulatory Read more
Leqembi® approved for the treatment of Alzheimer’s disease in China January 9, 2024 09:30 Regulatory Read more